All In Biotech

Drug Trial Radar · NCT00216840

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis

Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle and Calcipotriol in the Gel Vehicle in Scalp Psoriasis

Last checked: Nov 19, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,350 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,350

Actual

Start

Dec 2004

Primary completion

Not stated

Study completion Sep 2005

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Sep 22, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate whether once daily topical treatment for up to 8 weeks of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) gel is safe and more effective than betamethasone 0.5 mg/g (as dipropionate) in the gel vehicle and calcipotriol 50 mcg/g in the gel vehicle in patients with scalp psoriasis. The primary response criterion is the number of patients with absence of disease and very mild disease after 8 weeks of treatment.

Conditions

  • Psoriasis of Scalp

Interventions

  • Calcipotriol plus betamethasone dipropionate (LEO80185 gel)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. - Patients with "Controlled disease" ("Absence of disease" or "Very mild disease") according to investigator's global assessment of disease severity at week 8.

Locations

7 sites in 7 countries. Site status is shown where the registry gives one.

  • Universitair Ziekenhuis Sint Rafaël, Dienst Dermatologie

    Leuven, Belgium

  • Innovaderm Research Inc.

    Montreal, Quebec, Canada

  • Policlinic of Dermatology, Medical Reception Centre

    Turku, Finland

  • Hôpital Trousseau, Service de Dermatologie CHU Tours

    Tours, France

  • Georg-August-Universität Göttingen, Abteilung Dermatologie und Venerologie

    Göttingen, Germany

  • Universitair Medisch, Centrum St. Radboud, Afdeling Dermatologie

    Nijmegen, Netherlands

  • Royal Gwent Hospital, Department of Dermatology

    Newport, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.